Meta-analysis using hazard ratio (HR) was not feasible due to the availability of only a single study, which reported an HR of 0.131 (95% CI 0.016–1.068), suggesting a potential survival benefit with nedaplatin, although the result did not reach statistical significance [ 27 ].
← all excerpts
Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.
1
—
—